Recurrent Endocarditis in Persons Who Inject Drugs

Laura Rodger, Meera Shah, Esfandiar Shojaei, Seyed Hosseini, Sharon Koivu, Michael Silverman, Laura Rodger, Meera Shah, Esfandiar Shojaei, Seyed Hosseini, Sharon Koivu, Michael Silverman

Abstract

Background: Infective endocarditis (IE) is increasing among persons who inject drugs (PWID) and has high morbidity and mortality. Recurrent IE in PWID is not well described.

Methods: This was a retrospective cohort study conducted between February 2007 and March 2016. It included adult inpatients (≥18) at any of 3 tertiary care centers in London, Ontario, with definite IE based on the Modified Duke's Criteria. The objectives were to characterize recurrent IE in PWID, identify risk factors for recurrent IE, identify the frequency of fungal endocarditis, and establish whether fungal infection was associated with higher mortality.

Results: Three hundred ninety patients had endocarditis, with 212/390 in PWID. Sixty-eight of 212 (32%) PWID had a second episode, with 28/212 (12%) having additional recurrences. Second-episode IE was more common in PWID (11/178 [6.2%] vs 68/212 [32.1%]; P < .001). Peripherally inserted central catheter (PICC) line abuse was associated with increased risk of recurrent endocarditis (odds ratio [OR], 1.97; 95% confidence interval [CI], 1.01-3.87; P = .04). In PWID, fungal IE was more common in second episodes than first episodes (1/212 [0.5%] vs 5/68 [7.4%]; P = .004). Additionally, fungal infections were associated with mortality in second-episode IE in PWID with an adjusted OR of 16.49 (95% CI, 1.12-243.17; P = .041). Despite recurrent infection, likely due to continued drug use, there was a low rate of referral to addiction treatment (14/68 [20.6%]).

Conclusions: PWID have a high risk of recurrent endocarditis, particularly in patients who abuse PICC lines. Fungal endocarditis is more common in second-episode endocarditis and is associated with increased mortality. Consideration of empiric antifungal therapy in PWID with IE history and suspected IE should be considered.

Keywords: fungal endocarditis; infective endocarditis; opioids; persons who inject drugs; recurrent endocarditis.

© The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Kaplan-Meier survival analysis of PWID with second-episode infective endocarditis. Abbreviations: IE, infective endocarditis; PWID, persons who inject drugs.

References

    1. Jones CM, Christensen A, Gladden RM. Increases in prescription opioid injection abuse among treatment admissions in the United States, 2004–2013. Drug Alcohol Depend 2017;176:89–95.
    1. Wurcel AG, Anderson JE, Chui KKH, et al. . Increasing infectious endocarditis admissions among young people who inject drugs. Open Forum Infect Dis 2016;3:ofw157. doi:10.1093/ofid/ofw157.
    1. Fleischauer AT, Ruhl L, Rhea S, Barnes E. Hospitalizations for endocarditis and associated health care costs among persons with diagnosed drug dependence — North Carolina, 2010–2015. MMWR Morb Mortal Wkly Rep 2017;66(22):569–73.
    1. Glasgow JM, Vaughn-Sarrazin M, Kaboli PJ. Leaving against medical advice (AMA): risk of 30-day mortality and hospital readmission. J Gen Intern Med 2010; 25:926–9.
    1. Sharma M, Lamba W, Cauderella A, Guimond TH, Bayoumi AM. Harm reduction in hospitals. Harm Reduct J 2017;14(1):1–4.
    1. Gould FK, Denning DW, Elliott TSJ, et al. . Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2012;67(2):269–89.
    1. Baddour LM. Twelve-year review of recurrent native-valve infective endocarditis: a disease of the modern antibiotic era. Rev Infect Dis 1998;10(6):1163–70.
    1. Lossos IS, Oren R. Recurrent infective endocarditis. Postgrad Med J 1993;69(816):816–8.
    1. Huang G, Barnes EW, Peacock JE. Repeat infective endocarditis in persons who inject drugs: “Take Another Little Piece of my Heart”*. Open Forum Infect Dis 2018;X(X):XXX–XX.
    1. Ortiz-Bautista C, López J, García-Granja PE, et al. . Current profile of infective endocarditis in intravenous drug users: prognostic relevance of the valves involved. Int J Cardiol 2015;187(1):472–4.
    1. Cahill TJ, Prendergast BD. Infective endocarditis. Lancet 2016;387(10021):882–93.
    1. Murdoch DR. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century. Arch Intern Med 2009;169(5):463–73.
    1. Rodger L, Glockler-lauf SD, Shojaei E, et al. . Clinical characteristics and factors associated with mortality in first-episode infective endocarditis among persons who inject drugs. JAMA Netw Open 2018;1(7):1–15.
    1. Thalme A, Westling K, Julander I. In-hospital and long-term mortality in infective endocarditis in injecting drug users compared to non-drug users: a retrospective study of 192 episodes. Scand J Infect Dis 2007; 39:197–204.
    1. Colville T, Sharma V, Albouaini K. Infective endocarditis in intravenous drug users: a review article. Postgrad Med J 2016; 92:105–11.
    1. Arnold CJ, Johnson M, Bayer AS, et al. . Candida infective endocarditis: an observational cohort study with a focus on therapy. Antimicrob Agents Chemother 2015; 59:2365–73.
    1. Renzulli A, Carozza A, Romano G, et al. . Recurrent infective endocarditis: a multivariate analysis of 21 years of experience. Ann Thorac Surg 2001; 72(1):39–43.
    1. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg 2014; 12(12):1495–9.
    1. Baddour LM, Wilson WR, Bayer AS, et al. . Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation 2015; 132:1435–86.
    1. Palepu A, Cheung SS, Montessori V, et al. . Factors other than the Duke criteria associated with infective endocarditis among injection drug users. Clin Invest Med 2002; 25:118–25.
    1. Chu VH, Sexton DJ, Cabell CH, et al. . Repeat infective endocarditis: differentiating relapse from reinfection. Clin Infect Dis 2005; 41(3):406–9.
    1. Weir MA, Slater J, Jandoc R, Koivu S, Garg AX, Silverman M. The risk of infective endocarditis among people who inject drugs: a retrospective, population- based time series analysis. CMAJ 2019; 191(4):93–9.
    1. Hull SC, Jadbabaie F. When is enough enough? The dilemma of valve replacement in a recidivist intravenous drug user. Ann Thorac Surg 2014; 97(5):1486–7.
    1. Pettersson GB, Coselli JS, Hussain ST, et al. . 2016 The American Association for Thoracic Surgery (AATS) consensus guidelines: surgical treatment of infective endocarditis: executive summary. J Thorac Cardiovasc Surg 2017; 153(6):1241–58.e29.
    1. Alagna L, Park LP, Nicholson BP, et al. . Repeat endocarditis: analysis of risk factors based on the International Collaboration on Endocarditis - Prospective Cohort Study. Clin Microbiol Infect 2014; 20:566–75.
    1. Mansur AJ, Dal Bó CM, Fukushima JT, et al. . Relapses, recurrences, valve replacements, and mortality during the long-term follow-up after infective endocarditis. Am Heart J 2001; 141:78–86.
    1. Welton DE, Young JB, Gentry WO, et al. . Recurrent infective endocarditis: analysis of predisposing factors and clinical features. Am J Med 1979; 66(6):932–8.
    1. Pierrotti LC, Baddour LM. Fungal endocarditis, 1995–2000. Chest 2002; 122(1):302–10.
    1. Antinori S, Ferraris L, Orlando G, et al. . Fungal endocarditis observed over an 8-year period and a review of the literature. Mycopathologia 2014; 178:37–51.
    1. Tattevin P, Revest M, Lefort A, Michelet C, Lortholary O. Fungal endocarditis: current challenges. Int J Antimicrob Agents 2014; 44(4):290–4.
    1. Bodén MK, Flock JI. Evidence for three different fibrinogen-binding proteins with unique properties from Staphylococcus aureus strain Newman. Microb Pathog 1992; 12:289–98.
    1. Ellis ME, Al-Abdely H, Sandridge A, Greer W, Ventura W. Fungal endocarditis: evidence in the world literature, 1965–1995. Clin Infect Dis 2001; 32(1058–4838):50–62.
    1. Habib G, Lancellotti P, Antunes MJ, et al. . 2015 ESC guidelines for the management of infective endocarditis. Eur Heart J 2015; 36:3075–123.
    1. Caldarelli H, Locker A, Warshawsky B. A profile of people who inject drugs in London, Ontario report on the public health agency of Canada. Middlesex-London Heal Unit 2012.
    1. Poowanawittayakom N, Dutta A, Stock S, Touray S, Iii RTE, Levitz SM. Reemergence of intravenous drug use as risk factor for candidemia, Massachusetts, USA. Emerg Infect Dis 2019; 24(4):631–7.
    1. Hartnett KP, Jackson KA, Felsen C, et al. . Bacterial and fungal infections in persons who inject drugs — Western New York, 2017. Morb Mortal Wkly 2019; 68(26):2017–20.
    1. Østerdal OB, Salminen P-R, Jordal S, Sjursen H, Wendelbo Ø, Haaverstad R. Cardiac surgery for infective endocarditis in patients with intravenous drug use. Interact Cardiovasc Thorac Surg 2016; 22(5):633–40.
    1. Kaiser SP, Melby SJ, Zierer A, et al. . Long-term outcomes in valve replacement surgery for infective endocarditis. Ann Thorac Surg 2007; 83(1):30–5.
    1. Rosenthal ES, Karchmer AW, Theisen-toupal J, Castillo A. Suboptimal addiction interventions for patients hospitalized with injection drug use-associated infective endocarditis. Am J Med 2016; 129(5):481–5.
    1. Kasper KJ, Manoharan I, Hallam B, et al. . A controlled-release oral opioid supports S. aureus survival in injection drug preparation equipment and may increase bacteremia and endocarditis risk. PLoS One 2019; 14(8):e0219777.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit